Scott Dreyer Biography and Net Worth

Scott Dreyer was appointed Executive Vice President and Chief Commercial Officer in July 2018. Mr. Dreyer joined Collegium in January 2018 as Senior Vice President of Sales, Marketing, Commercial Capabilities and Training. He has over 25 years of commercial experience across sales, marketing, commercial operations and strategic planning, all within the biopharma industry. Most recently, Mr. Dreyer was Senior Vice President, Marketing and Commercial Operations for The Medicines Company. Prior to joining The Medicines Company, he was Vice President and Chief Marketing Officer-US at Biogen. Prior to Biogen, Mr. Dreyer held various commercial leadership positions of increasing responsibility at Merck & Co including Vice President-US Hospital and Oncology Sales and Commercial Operations, Vice President-US Primary Care Sales, Executive Director US Regional Marketing Leader – Neuroscience, Executive Director Customer Marketing and Solutions, Sr. Director of Strategic Planning and Director of Cardiovascular Marketing. Throughout his career, he has been involved in the commercialization of over 35 products across more than 15 therapeutic areas and launched over 20 products. Mr. Dreyer received his B.S. degree in Biology from Messiah College in Grantham, PA.

What is Scott Dreyer's net worth?: The estimated net worth of Scott Dreyer is at least $2.62 million as of March 3rd, 2026. Mr. Dreyer owns 71,770 shares of Collegium Pharmaceutical stock worth more than $2,620,323 as of May 7th. This net worth estimate does not reflect any other investments that Mr. Dreyer may own. Learn More about Scott Dreyer's net worth.
How do I contact Scott Dreyer?: The corporate mailing address for Mr. Dreyer and other Collegium Pharmaceutical executives is 100 Technology Center Drive, Stoughton MA, 02072. Collegium Pharmaceutical can also be reached via phone at (781) 713-3699 and via email at [email protected]. Learn More on Scott Dreyer's contact information.
Has Scott Dreyer been buying or selling shares of Collegium Pharmaceutical?: Scott Dreyer has not been actively trading shares of Collegium Pharmaceutical over the course of the past ninety days. Most recently, Scott Dreyer sold 49,976 shares of the business's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a transaction totalling $2,019,530.16. Following the completion of the sale, the executive vice president now directly owns 71,770 shares of the company's stock, valued at $2,900,225.70. Learn More on Scott Dreyer's trading history.
Who are Collegium Pharmaceutical's active insiders?: Collegium Pharmaceutical's insider roster includes Rita Balice-Gordon (Director), Garen Bohlin (Director), Joseph Ciaffoni (CEO), Joseph Ciaffoni (Pres), David Dieter (EVP), Scott Dreyer (EVP), John Freund (Director), Michael Heffernan (Director), Shirley Kuhlmann (EVP), Gino Santini (Director), Thomas Smith (EVP), Colleen Tupper (CFO), and Colleen Tupper (Exec. VP & CFO ). Learn More on Collegium Pharmaceutical's active insiders.
Are insiders buying or selling shares of Collegium Pharmaceutical?: During the last year, insiders at the specialty pharmaceutical company sold shares 11 times. They sold a total of 177,595 shares worth more than $7,029,253.67. The most recent insider tranaction occured on March, 18th when EVP David Dieter sold 13,976 shares worth more than $488,041.92. Insiders at Collegium Pharmaceutical own 1.9% of the company. Learn More about insider trades at Collegium Pharmaceutical.
Information on this page was last updated on 3/18/2026.

Scott Dreyer Insider Trading History at Collegium Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/3/2026	Sell	49,976	$40.41	$2,019,530.16	71,770
12/8/2025	Sell	17,600	$48.17	$847,792.00	103,613
8/18/2025	Sell	16,389	$38.21	$626,223.69	103,613
8/13/2025	Sell	4,861	$38.03	$184,863.83	103,613
3/14/2025	Sell	2,255	$30.00	$67,650.00	124,421
5/24/2024	Sell	56,807	$33.98	$1,930,301.86	105,902
1/16/2024	Sell	23,560	$32.28	$760,516.80	111,322
3/1/2023	Sell	13,324	$26.70	$355,750.80	134,882
1/9/2023	Sell	17,834	$27.39	$488,473.26	102,798
2/18/2022	Sell	10,559	$21.61	$228,179.99
12/15/2021	Sell	5,693	$18.33	$104,352.69
1/15/2021	Sell	1,322	$22.89	$30,260.58	44,395
7/13/2020	Sell	1,429	$17.01	$24,307.29	47,847
5/13/2020	Sell	4,434	$22.61	$100,252.74	48,441
1/14/2020	Sell	1,321	$23.87	$31,532.27	35,716
7/11/2019	Sell	2,857	$12.31	$35,169.67	40,596

Scott Dreyer Buying and Selling Activity at Collegium Pharmaceutical

Collegium Pharmaceutical Company Overview

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Today's Range

Now: $39.35

$35.81

$39.55

50 Day Range

MA: $35.46

$31.99

$45.75

2 Week Range

Now: $39.35

$26.81

$50.79

Volume

498,976 shs

Average Volume

506,068 shs

Market Capitalization

$1.28 billion

P/E Ratio

23.01

Dividend Yield

N/A

Beta

0.76